High-quality clinical trials define the landscape of 2026 Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to transform patient care while navigating the complex path toward regulatory approval.
Dyne targets rare neuromuscular conditions with a proprietary delivery platform, while Viking focuses on the large metabolic and endocrine markets. Comparing the two helps you understand whether to bet on special orphan diseases or highly sought-after weight loss treatments. Both companies are in the clinical stage, meaning they are still testing products and do not yet have repeat sales.
The case of Dyne Therapeutics
Dyne focuses on the FOCE platform to deliver targeted therapies for neuromuscular diseases such as Duchenne muscular dystrophy and Pompe disease. Using its proprietary platform, the company aims to overcome the limitations of current therapies by improving gene drug delivery to muscle tissue. It is currently not generating trading capital and is dependent on a significant loan agreement with Hercules Capital for its operating expenses. The company also relies on various third-party organizations to manufacture its drug components and conduct its clinical trials.
In FY 2025, the company reported revenue of $0.0. The business recorded a net loss of approximately $446.2 million for the year. This represents a significant increase in losses from the $317.4 million loss seen in the previous fiscal year. Management has made it a priority to advance candidates for their best product, which requires a lot of money for late-stage courses. These rising costs are typical for firms in the biotech sector as they invest heavily in research and development.
As of its December 2025 balance sheet, the debt-to-equity ratio is 0.19x. This metric compares total debt to stockholders’ equity to see how dependent a company is on creditors. The current ratio, which measures the ability to pay off short-term debt with current assets, is about 22.3x. A ratio above 1.0 generally suggests a healthy cushion to meet imminent financial obligations. Free cash flow, which is cash from operations minus capital expenditures, was nearly negative at $405.1 million in FY 2025.
The case of Viking Therapeutics
Viking Therapeutics is developing new treatments for metabolic and endocrine disorders, with a particular focus on its weight loss candidate VK2735. Subject to the master license agreement with Ligand Pharmaceuticals rights to its most valuable drug properties. Besides weight loss, the company is also targeting rare diseases like X-linked adrenoleukodystrophy to diversify its clinical pipeline. The company also maintains a key agreement with Corden Pharma to manage the production of its active pharmaceutical ingredients.
Similar to its peers among biotech stocks, the company reported $0.0 in revenue for FY 2025. It saw a net loss of close to $359.6 million during the year. This net loss was significantly widened from a loss of approximately $110.0 million reported in the previous fiscal year. Increased clinical trial activity and labor costs have driven higher spending levels as the company scales its operations.
According to its December 2025 balance sheet, the debt-to-equity ratio is 0.0x. This figure shows that the company currently has no debt relative to its equity. The current ratio is around 9.3x, suggesting that it has enough liquid assets to cover its future liabilities many times over. Free cash flow for FY 2025 came in at about $278.7 million negative. Free cash flow is calculated by subtracting the cost of capital from the cash flow from operations and represents the money a company generates after taking care of its assets.
Risk profile comparison
Dyne faces significant risks related to its dependence on foreign capital to finance ongoing operations. The company has accumulated a large deficit, and any failure to secure new funding could force it to halt development. Its product candidates are unproven and face high failure rates in clinical trials. In addition, it relies on single-source suppliers of drug components, and the neuromuscular market is full of well-funded competitors.
Viking is largely dependent on a license agreement with Ligand Pharmaceuticals, and any breach of that contract could terminate certain drug programs. It also faces concentration risk by relying on Corden Pharma for its manufacturing needs. The company is currently under investigation for possible violations of federal securities laws. Finally, it faces a lot of competition from big industries like Eli Lilly again Novo Nordisk.
Comparison of measurements
Dyne Therapeutics appears cheap based on the Forward P/E, which measures the price relative to future earnings estimates. No company currently produces sales to calculate the P/S ratio.
The sector benchmark uses the SPDR XLV sector ETF.
Valuation metrics are derived from Financial Modeling Prep (FMP) and may differ from other data providers.
What stock should I buy in 2026?
I would go with Viking Therapeutics. Both companies are doing important work, but they’re pursuing opportunities of very different sizes, and that’s important when assessing long-term upside.
Yes, Dyne Therapeutics is making progress in rare neuromuscular diseases like Duchenne muscular dystrophy, and its recent clinical data has been encouraging. But rare disease markets are limited in size, and the road to approval is long.
Viking is playing on one of the biggest health care opportunities of our generation. Treating obesity is a large and rapidly growing market, and Viking has a drug, VK2735, that shows strong weight loss results in both an injectable and oral formulation. Its phase 3 program is ongoing, and the company recently added another obesity treatment to its pipeline. The competitive landscape includes giants like Eli Lilly and Novo Nordisk, so this is not an easy road. But the upside if Viking medicine succeeds is enormous.
For a patient, long-term investor, that kind of opportunity is hard to pass up.
Should you buy stock in Dyne Therapeutics right now?
Before buying stock in Dyne Therapeutics, consider the following:
I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and Dyne Therapeutics was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.
Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $382,359!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,201,390!*
Now, it’s worth noting Stock Advisor’s average return is 883% — a market-beating performance that crushes the S&P 500’s 205%. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.
See 10 stocks »
*Stock Advisor returns as of June 26, 2026.
Sarah Appino has no position in any of the specified stocks. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends Viking Therapeutics. The Motley Fool has disclosure policy.
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is the Best to Buy in 2026? was first published by The Motley Fool
